{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"5.170","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"567,006,000","primaryexch":"HKEX","ric":"1061.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.5414,"inline_upper_strike_price":"","sedol":"6370291","am":"2.93","iv":"","ew_strike":"","as":"5.170","geographic_focus":null,"incorpin":"Cayman Islands","etp_baseCur":null,"ew_amt_os":"","bd":"5.110","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-26 10:38:37.0","lo52":"2.260","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"Ngiam Mia Je Patrick","underlying_ric":"1061.HK","hi52":"6.120","issuer_name":"Essex Bio-Technology Ltd.","h_share_flag":false,"ew_sub_per_from":"","div_yield":"2.51","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"5.070","mkt_cap":"2.93","f_aum_hkd":null,"ew_sub_per_to":"","ls":"5.170","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"+0.040","aum":"","issued_shares_class_B":null,"vo":"574.00","secondary_listing_flag":false,"listing_date":"27 Jun 2001","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Essex Bio-Technology Ltd.","nm_s":"ESSEX BIO-TECH","sym":"1061","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"Essex Bio-Technology Ltd is an investment holding company mainly engaged in the production and sale of biopharmaceuticals for the treatment of body surface trauma and eye injuries. The Company operates its business through three segments. The Surgical segment is engaged in the development, manufacture and sale of Beifuji series products such as Beifuji spray, Beifuji lyophilized powder, Beifuxin gel and others. The Ophthalmology segment is engaged in the development, manufacture and sale of Beifuji series products such as Beifushu eye drops, Beifushu eye gel, Beifushu single-dose eye drops and others. The Provision of Services segment is engaged in the provision of healthtech e-platform related medical services.","op":"5.110","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"23/06/2011","hsic_sub_sector_classification":"Pharmaceuticals","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Room 3206, West Tower<br/>Shun Tak Centre<br/>168-200 Connaught Road<br/>Hong Kong","pc":"+0.78","days_to_expiry":null,"underlying_code":null,"pe":"9.55","eps_ccy":"HKD","hdr":false,"launch_date":"","hc":"5.130","isin":"KYG312371035","moneyness":""}},"qid":"1758890518006"}
